End-of-day quote
Taipei Exchange
18:00:00 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
79.9
TWD
|
+7.97%
|
|
+30.77%
|
+94.88%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,869
|
1,500
|
1,093
|
1,042
|
784
|
875.9
|
Enterprise Value (EV)
1 |
1,569
|
1,361
|
974.8
|
882.6
|
687.7
|
799.4
|
P/E ratio
|
39.7
x
|
24.3
x
|
31.8
x
|
18.3
x
|
18.4
x
|
76
x
|
Yield
|
2.26%
|
3.67%
|
2.72%
|
4.08%
|
2.72%
|
0.49%
|
Capitalization / Revenue
|
4.07
x
|
2.94
x
|
2.24
x
|
2.05
x
|
1.58
x
|
1.88
x
|
EV / Revenue
|
3.42
x
|
2.67
x
|
1.99
x
|
1.74
x
|
1.39
x
|
1.71
x
|
EV / EBITDA
|
20.5
x
|
14.6
x
|
18.7
x
|
14.6
x
|
23
x
|
78.3
x
|
EV / FCF
|
89.6
x
|
19.2
x
|
28.6
x
|
13.9
x
|
-33.7
x
|
300
x
|
FCF Yield
|
1.12%
|
5.2%
|
3.5%
|
7.21%
|
-2.97%
|
0.33%
|
Price to Book
|
3.79
x
|
2.92
x
|
1.98
x
|
1.68
x
|
1.25
x
|
1.42
x
|
Nbr of stocks (in thousands)
|
21,090
|
21,159
|
21,219
|
21,262
|
21,362
|
21,362
|
Reference price
2 |
88.60
|
70.90
|
51.50
|
49.00
|
36.70
|
41.00
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/24/22
|
3/31/23
|
3/18/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
459.4
|
509.4
|
488.9
|
508.4
|
495.8
|
466.8
|
EBITDA
1 |
76.66
|
93.47
|
52.19
|
60.4
|
29.85
|
10.21
|
EBIT
1 |
54.07
|
66.72
|
20.92
|
35.24
|
3.787
|
-15.88
|
Operating Margin
|
11.77%
|
13.1%
|
4.28%
|
6.93%
|
0.76%
|
-3.4%
|
Earnings before Tax (EBT)
1 |
52.04
|
75.22
|
37.28
|
63.69
|
47.35
|
8.903
|
Net income
1 |
47.35
|
62.67
|
34.62
|
56.98
|
42.78
|
11.53
|
Net margin
|
10.31%
|
12.3%
|
7.08%
|
11.21%
|
8.63%
|
2.47%
|
EPS
2 |
2.232
|
2.920
|
1.620
|
2.677
|
2.000
|
0.5396
|
Free Cash Flow
1 |
17.51
|
70.82
|
34.08
|
63.61
|
-20.41
|
2.664
|
FCF margin
|
3.81%
|
13.9%
|
6.97%
|
12.51%
|
-4.12%
|
0.57%
|
FCF Conversion (EBITDA)
|
22.84%
|
75.77%
|
65.31%
|
105.32%
|
-
|
26.08%
|
FCF Conversion (Net income)
|
36.98%
|
113%
|
98.45%
|
111.65%
|
-
|
23.11%
|
Dividend per Share
2 |
2.000
|
2.600
|
1.400
|
2.000
|
1.000
|
0.2000
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/24/22
|
3/31/23
|
3/18/24
|
Fiscal Period: December |
2022 Q1
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
-
|
129.6
|
120
|
EBITDA
|
-
|
-
|
-
|
EBIT
1 |
-
|
2.143
|
-4.01
|
Operating Margin
|
-
|
1.65%
|
-3.34%
|
Earnings before Tax (EBT)
1 |
-
|
7.98
|
1.869
|
Net income
1 |
14.31
|
5.92
|
2.548
|
Net margin
|
-
|
4.57%
|
2.12%
|
EPS
2 |
0.6700
|
0.2800
|
0.1200
|
Dividend per Share
|
-
|
-
|
-
|
Announcement Date
|
5/5/22
|
8/3/22
|
11/9/22
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
300
|
139
|
118
|
159
|
96.3
|
76.4
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
17.5
|
70.8
|
34.1
|
63.6
|
-20.4
|
2.66
|
ROE (net income / shareholders' equity)
|
11.9%
|
12.3%
|
6.41%
|
9.64%
|
6.89%
|
1.91%
|
ROA (Net income/ Total Assets)
|
6.92%
|
6.38%
|
1.78%
|
2.8%
|
0.29%
|
-1.26%
|
Assets
1 |
684.3
|
982.9
|
1,950
|
2,036
|
14,730
|
-914.3
|
Book Value Per Share
2 |
23.40
|
24.20
|
26.00
|
29.20
|
29.30
|
28.90
|
Cash Flow per Share
2 |
14.20
|
11.50
|
8.880
|
10.10
|
5.610
|
4.530
|
Capex
1 |
27.8
|
18
|
15.5
|
8.16
|
33.5
|
21
|
Capex / Sales
|
6.05%
|
3.54%
|
3.16%
|
1.61%
|
6.76%
|
4.5%
|
Announcement Date
|
4/1/19
|
3/31/20
|
3/31/21
|
3/24/22
|
3/31/23
|
3/18/24
|
|
1st Jan change
|
Capi.
|
---|
| +94.88% | 52.54M | | -42.89% | 7.8B | | +6.77% | 3.53B | | -1.35% | 2.24B | | -27.06% | 1.84B | | -21.23% | 1.66B | | +9.31% | 951M | | +29.42% | 811M | | -12.66% | 670M | | -26.12% | 533M |
Bio Diagnostics & Testing
|